March 27, 2019
Nippon Boehringer Ingelheim said on March 26 that it has obtained orphan drug designation for its tyrosine kinase inhibitor Ofev (nintedanib) for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis. Ofev was approved in Japan in 2015...read more